BioCentury
ARTICLE | Company News

Epizyme promotes Rhodes to president

July 3, 2013 11:13 PM UTC

Epizyme Inc. (NASDAQ:EPZM) promoted Jason Rhodes to president from EVP. He will remain CFO and treasurer. Epizyme raised $88.7 million in an IPO earlier this year. The company's EPZ-5676 is in a Phase I trial to treat leukemia with rearrangements in either the histone methyltransferase myeloid-lymphoid or mixed-lineage leukemia (MLL; HRX) gene. Celgene Corp. (NASDAQ:CELG) has ex-U.S. rights to the histone methyltransferase DOT1L (DOT1L) inhibitor under a 2012 deal (see BioCentury, April 30, 2012). ...